Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in ...

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Despite securing the industry’s first approval for familial chylomicronemia syndrome, BMO Capital Markets believes that ...

While layoffs have slowed in the second half of the year, according to BioSpace data, companies including Bayer, Bristol ...

Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 ...

Indeed, there weren’t many more biotech IPOs in 2024 than in 2023, and the companies that did venture out this year struggled ...

Tenaya’s share slump following the TN-201 data drop could be due to its “significantly lower” level of RNA expression in the ...

Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of ...